Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report
Abstract The advent of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but their association with immune-related adverse events presents a new and complex challenge for clinicians. In this report, we present the case of a 60-year-old Han Chinese woman who developed myasthenia gra...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMC
2025-07-01
|
| Collection: | BMC Neurology |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s12883-025-04288-0 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|